DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • Spain
  • /
  • Materials
Author Program NEWCreate Narrative
ECR logo

Ercros, S.A. Stock Price

BME:ECR Community·€319.1m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 9 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

ECR Share Price Performance

€3.49
0.69 (24.64%)
​
€3.49
0.69 (24.64%)
​
Price €3.49
Fri, 11 Sep 26
Share Pricen/a

ECR Community Narratives

There are no narratives available yet.
Create Narrative
There are no community narratives available.

Trending Discussion

No trending discussion available.

Recently Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Fair value with imperfect balance sheet.

1 Risk
2 Rewards
View Full Analysis

Ercros, S.A. Key Details

€636.0m

Revenue

€437.5m

Cost of Revenue

€198.6m

Gross Profit

€226.8m

Other Expenses

-€28.2m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
-0.31
31.22%
-4.44%
73.3%
View Full Analysis

About ECR

Founded
1817
Employees
1346
CEO
Joao Maria Guimaraes Jose Mello
WebsiteView website
www.ercros.es

Ercros, S.A., together with its subsidiaries, manufactures and sells chemical and pharmaceutical products in Spain and internationally. It operates through three segments: Chlorine Derivatives, Intermediate Chemicals, and Pharmaceuticals. The company offers ammonia, caustic soda and potash, chlorine chloroisocyanurates, dichloroethane, ercrosbio, hydrochloric acid, hydrogen peroxide, polyvinyl chloride, potassium carbonate, PVC compounds, sodium chlorate, sodium chlorite, sodium hypochlorite, sulfuric acid, and vinyl chloride. It also provides dipentaerythritol, ercrosgreen + resins, formaldehyde, methanol, moulding compounds, paraformaldehyde, pentaerythritol, and sodium formate. In addition, the company offers generic active pharmaceutical ingredients, including amlodipine besylate, azithromycin, clarithromycin, erythromycin, famotidine, fosfomycin, and fusidic acid, as well as customized production of antibiotics, anti-hypertensives, and anti-ulcer drugs. It exports its products. The company was formerly known as S.A. Cros and changed its name to Ercros, S.A. in June 1989. Ercros, S.A. was founded in 1817 and is headquartered in Barcelona, Spain.

Recent ECR News & Updates

Recent updates

No updates

Ercros, S.A. Competitors

ENC logo

ENCE Energía y Celulosa

Symbol: BME:ENC
Market cap: €603.6m
MCM logo

Miquel y Costas & Miquel

Symbol: BME:MCM
Market cap: €499.6m
TUB logo

Tubacex

Symbol: BME:TUB
Market cap: €345.4m
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide